---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-083290"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2022-12-28T23:59:59+00:00"
generated_at: "2026-06-20T22:26:38.562477+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Relmada extends key man provisions in esmethadone license to Dec 31, 2027

## Summary
- Amendment No. 2 extends the 'Key Man' termination-protection period from Dec 31, 2022 to Dec 31, 2027.
- Licensor may terminate license if CEO Sergio Traversa is fired without cause or his role is materially reduced.
- License covers esmethadone (REL-1017) for psychiatric use; no other terms of the license were changed.
- Extension locks in CEO-linked protections for an additional five years through 2027.

## SEC filing metadata
- accession: 0001213900-22-083290
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2022-12-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390022083290/0001213900-22-083290-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390022083290/ea170963-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-083290
- JSON: https://secwatch.observer/filing/0001213900-22-083290.json
- Plain text: https://secwatch.observer/filing/0001213900-22-083290.txt

## Key facts
- Material Agreements
  RELMADA THERAPEUTICS, INC. amended License Agreement with Drs. Charles E. Inturrisi and Paolo Manfredi (effective 2022-12-27).
  - Action: amendment
  - Agreement: license
  - Counterparty: Drs. Charles E. Inturrisi and Paolo Manfredi
  - Effective: 2022-12-27
  source text: On December 27, 2022, the Licensor and the Company entered into an Amendment No. 2 to the License Agreement extending the duration of the “Key Man” provisions of the License Agreement
  evidence_url: https://www.sec.gov/Archives/edgar/data/1553643/000121390022083290/0001213900-22-083290-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.